GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been assigned an average rating of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $14.20.

A number of brokerages have recently weighed in on GOVX. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Friday, November 15th. D. Boral Capital restated a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research report on Wednesday, December 18th. Finally, Alliance Global Partners initiated coverage on GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 price target for the company.

Institutional Trading of GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs as of its most recent SEC filing. 6.09% of the stock is currently owned by institutional investors and hedge funds.

GeoVax Labs Price Performance

NASDAQ:GOVX opened at $2.44 on Tuesday. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. The business has a fifty day moving average of $2.38 and a 200-day moving average of $2.79.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.38. The company had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same period in the previous year, the company earned ($4.80) EPS. Analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.